Reference
Maina N, et al. Heterozygous pathogenic TNFRSF13B (TACI) variant in a patient with pediatric onset, difficult-to-treat inflammatory bowel disease. Journal of Clinical Immunology 38: 367-368 abstr. 79, No. 3, Apr 2018. Available from: URL: http://doi.org/10.1007/s10875-018-0485-z [abstract] - USA
Rights and permissions
About this article
Cite this article
Adalimumab/infliximab. Reactions Weekly 1708, 25 (2018). https://doi.org/10.1007/s40278-018-48118-2
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-018-48118-2